Afficher la notice abrégée

dc.creatorKoliarakis I., Psaroulaki A., Nikolouzakis T.K., Kokkinakis M., Sgantzos M.N., Goulielmos G., Androutsopoulos V.P., Tsatsakis A., Tsiaoussis J.en
dc.date.accessioned2023-01-31T08:43:35Z
dc.date.available2023-01-31T08:43:35Z
dc.date.issued2018
dc.identifier.issn11070625
dc.identifier.urihttp://hdl.handle.net/11615/74970
dc.description.abstractColon holds a complex microbial community, which is crucial for maintaining homeostasis and regulating metabolic functions, supporting the intestinal barrier and controlling immune responses. Previous studies have supported a link between intestinal microbiota and colorectal cancer (CRC). Based on these findings, the present review analyzed the numerous interactions that occur between microbiota and CRC, starting from the role of intestinal microbiota in colonic homoeostasis. Intestinal microbiota is a cause of CRC and involves various mechanisms such as chronic inflammation, the production of genotoxins causing DNA impairment and/or the biosynthesis of toxic compounds. Moreover, basic metabolic factors such as short-chain fatty acids (SCFAs) and bile acids are included in CRC pathogenesis. Different pathogenic pathways have been reported among different CRC regions (proximal or distal). Variations in the microbial populations are reported between the CRC from these colonic sites, possibly reflecting the bacterial dysbiosis and biofilm distribution. Bowel preparation is essential prior to colonoscopy and surgery; there is, however, minor consensus on the effects of this procedure on intestinal microbiota, notably with regard to the long-term outcomes. With regard to the therapeutic strategy in CRC, the intestinal microbiota is further involved in the modulation of the host response to chemotherapeutic agents (5-fluorouracil and irinotecan) by the interference with drug efficacy and by adverse effects and associated toxicity. In addition, the newly emerged research on CRC immunotherapy reveals an important interplay between intestinal microbiota and the immune system, which includes the possibility of targeting microbiota for the enhancement of anticancer treatment. Additional studies will further clarify the interaction between microbiota and CRC, resulting in the development of alternative therapeutic strategies by manipulating microbiota composition. © 2018 Zerbinis Publications. All Rights Reserved.en
dc.language.isoenen
dc.sourceJournal of B.U.ON.en
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85053228089&partnerID=40&md5=a837c69c62aae9b8f159dd1ca935a8cf
dc.subjectantineoplastic monoclonal antibodyen
dc.subjectbile aciden
dc.subjectdendritic cell vaccineen
dc.subjectDNAen
dc.subjectfluorouracilen
dc.subjectirinotecanen
dc.subjectshort chain fatty aciden
dc.subjectprobiotic agenten
dc.subjectascending colonen
dc.subjectbiofilmen
dc.subjectcancer chemotherapyen
dc.subjectcancer immunotherapyen
dc.subjectcarcinogenesisen
dc.subjectcell therapyen
dc.subjectcolonoscopyen
dc.subjectcolorectal canceren
dc.subjectdescending colonen
dc.subjectdrug efficacyen
dc.subjectdrug safetyen
dc.subjecthumanen
dc.subjectimmune responseen
dc.subjectintestine floraen
dc.subjectintestine preparationen
dc.subjectnonhumanen
dc.subjectReviewen
dc.subjectanimalen
dc.subjectcolorectal tumoren
dc.subjectdrug effecten
dc.subjectgastrointestinal tracten
dc.subjectintestine floraen
dc.subjectmicrobiologyen
dc.subjectAnimalsen
dc.subjectColorectal Neoplasmsen
dc.subjectGastrointestinal Microbiomeen
dc.subjectGastrointestinal Tracten
dc.subjectHumansen
dc.subjectProbioticsen
dc.subjectZerbinis Publicationsen
dc.titleIntestinal microbiota and colorectal cancer: A new aspect of researchen
dc.typeotheren


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée